DOP2020000004A - Carboxamidas como moduladores de los canales de sodio - Google Patents
Carboxamidas como moduladores de los canales de sodioInfo
- Publication number
- DOP2020000004A DOP2020000004A DO2020000004A DO2020000004A DOP2020000004A DO P2020000004 A DOP2020000004 A DO P2020000004A DO 2020000004 A DO2020000004 A DO 2020000004A DO 2020000004 A DO2020000004 A DO 2020000004A DO P2020000004 A DOP2020000004 A DO P2020000004A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- carboxamides
- modulators
- sodium channels
- compounds
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan compuestos y sus sales farmacéuticamente aceptables, de utilidad como inhibidores de canales de sodio. Además, se proporcionan composiciones farmacéuticas que comprenden los compuestos o sales farmacéuticamente aceptables y métodos de uso de los compuestos, sales farmacéuticamente aceptables y composiciones farmacéuticas en el tratamiento de varios trastornos, incluyendo dolor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762531313P | 2017-07-11 | 2017-07-11 | |
US201762608283P | 2017-12-20 | 2017-12-20 | |
PCT/US2018/041649 WO2019014352A1 (en) | 2017-07-11 | 2018-07-11 | CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2020000004A true DOP2020000004A (es) | 2020-07-15 |
Family
ID=63036498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2020000004A DOP2020000004A (es) | 2017-07-11 | 2020-01-08 | Carboxamidas como moduladores de los canales de sodio |
Country Status (23)
Country | Link |
---|---|
US (3) | US10647661B2 (es) |
EP (1) | EP3651752A1 (es) |
JP (1) | JP7277431B2 (es) |
KR (1) | KR20200026987A (es) |
CN (1) | CN111065383A (es) |
AU (1) | AU2018300150A1 (es) |
BR (1) | BR112020000553A2 (es) |
CA (1) | CA3069720A1 (es) |
CL (1) | CL2020000075A1 (es) |
CO (1) | CO2020000145A2 (es) |
CR (1) | CR20200064A (es) |
DO (1) | DOP2020000004A (es) |
EC (1) | ECSP20003147A (es) |
IL (1) | IL271948A (es) |
JO (1) | JOP20200001A1 (es) |
MA (1) | MA49566A (es) |
PE (1) | PE20201164A1 (es) |
PH (1) | PH12020500066A1 (es) |
SG (1) | SG11202000230VA (es) |
TN (1) | TN2020000001A1 (es) |
TW (1) | TW201920081A (es) |
UY (1) | UY37806A (es) |
WO (1) | WO2019014352A1 (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20151781A1 (es) | 2013-01-31 | 2015-12-02 | Vertex Pharma | Piridonamidas como moduladores de canales de sodio |
CA2918365C (en) | 2013-07-19 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
KR102435145B1 (ko) | 2013-12-13 | 2022-08-24 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드의 프로드럭 |
IL270680B (en) | 2017-05-16 | 2022-06-01 | Vertex Pharma | Deuterium-converted pyridone amides and their prodrugs as sodium channel modulators |
BR112020000553A2 (pt) | 2017-07-11 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | carboxamidas como moduladores de canal de sódio |
US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
CN112004817B (zh) | 2018-02-15 | 2023-06-23 | 弗特克斯药品有限公司 | 作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法 |
AU2019301628A1 (en) * | 2018-07-09 | 2021-01-28 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
KR20210019119A (ko) | 2018-07-09 | 2021-02-19 | 리버 인스티튜트, 아이엔씨 | Nav1.8을 억제하기 위한 피리다진(PYRIDAZINE) 화합물 |
US11377438B2 (en) * | 2018-11-02 | 2022-07-05 | Merck Sharp & Dohme Llc | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors |
WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
WO2020151728A1 (zh) * | 2019-01-25 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
CN114599657A (zh) | 2019-08-14 | 2022-06-07 | 弗特克斯药品有限公司 | Cftr调节剂的结晶形式 |
WO2021032074A1 (zh) * | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用 |
CN113906013B (zh) * | 2019-09-12 | 2024-03-12 | 上海济煜医药科技有限公司 | 吡啶氮氧化合物及其制备方法和用途 |
BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
CN110950797A (zh) * | 2019-12-06 | 2020-04-03 | 丽水绿氟科技有限公司 | 一种2-三氟甲基-3-氟-4-吡啶甲酸及其衍生物的制备方法 |
CN110937994B (zh) * | 2019-12-10 | 2022-04-22 | 浙江大洋生物科技集团股份有限公司 | 二步氯化法合成2,4-二氯-6-氟苯甲酰氯的方法 |
CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
EP4146628A1 (en) | 2020-05-06 | 2023-03-15 | Bayer Aktiengesellschaft | Pyridine (thio)amides as fungicidal compounds |
BR112022023012A2 (pt) | 2020-05-12 | 2022-12-20 | Bayer Ag | (tio)amidas de triazina e pirimidina como compostos fungicidas |
IL299180A (en) | 2020-06-17 | 2023-02-01 | Merck Sharp & Dohme Llc | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS |
CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
CN111920796A (zh) * | 2020-08-28 | 2020-11-13 | 南京医科大学 | 化合物在制备治疗癫痫药物中的应用 |
CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
CN114031518B (zh) * | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
TW202300147A (zh) | 2021-03-11 | 2023-01-01 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物晶型及其應用 |
WO2022216573A1 (en) | 2021-04-05 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
US20220380338A1 (en) | 2021-05-07 | 2022-12-01 | Merck Sharp & Dohme Llc | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
CA3221960A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
WO2022256702A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
PE20241335A1 (es) | 2021-06-04 | 2024-07-03 | Vertex Pharma | N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio |
WO2022256679A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
CA3222006A1 (en) * | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
EP4346818A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
AR126670A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
AR126669A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
WO2023138599A1 (zh) | 2022-01-18 | 2023-07-27 | 成都康弘药业集团股份有限公司 | 芳香并环类Nav1.8抑制剂及其用途 |
WO2023186102A1 (zh) * | 2022-04-02 | 2023-10-05 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂及其用途 |
WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
WO2023207949A1 (zh) * | 2022-04-25 | 2023-11-02 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
TW202413335A (zh) * | 2022-06-22 | 2024-04-01 | 大陸商武漢人福創新藥物研發中心有限公司 | Nav1.8抑制劑 |
WO2024041613A1 (zh) * | 2022-08-24 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
WO2024046253A1 (zh) * | 2022-08-28 | 2024-03-07 | 上海汇伦医药股份有限公司 | 一种钠通道调节剂及其应用 |
WO2024046409A1 (zh) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
WO2024054622A2 (en) * | 2022-09-09 | 2024-03-14 | Latigo Biotherapeutics, Inc. | Sodium channel blocking compounds, derivatives thereof, and methods of their use |
WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
WO2024146632A1 (zh) * | 2023-01-06 | 2024-07-11 | 西藏海思科制药有限公司 | 一种四氢噻吩衍生物及其在医药上的应用 |
WO2024153856A1 (en) * | 2023-01-18 | 2024-07-25 | Orion Corporation | Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide |
Family Cites Families (249)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1025305A (en) | 1910-07-29 | 1912-05-07 | Andrew Rasmussen | Feeding means for power hacksaw-machines. |
US1008714A (en) | 1910-12-27 | 1911-11-14 | Henry M Hammer | Delinting-machine. |
US2511231A (en) | 1949-03-26 | 1950-06-13 | Eastman Kodak Co | 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography |
US2688617A (en) | 1951-07-17 | 1954-09-07 | American Cyanamid Co | Sulfonated dihalogeno diaminostilbenes |
US2657134A (en) | 1951-12-05 | 1953-10-27 | Eastman Kodak Co | Photographic emulsion with colored couplers containing isophthalic ester groups |
BE516025A (es) | 1951-12-05 | |||
US2725292A (en) | 1952-05-15 | 1955-11-29 | Eastman Kodak Co | Colored couplers containing solubilizing groups |
US2710802A (en) | 1953-03-16 | 1955-06-14 | Eastman Kodak Co | Dialkyl-5-(oxanilamido) isophthalate couplers for color photography |
US2710803A (en) | 1953-03-26 | 1955-06-14 | Eastman Kodak Co | Color couplers containing hydroxyalkyl groups |
BE528163A (es) | 1953-04-17 | |||
BE531589A (es) | 1953-09-02 | |||
US4218765A (en) | 1974-10-03 | 1980-08-19 | Standard Oil Company (Indiana) | Two-dimensional frequency domain filtering |
DE2623228C3 (de) | 1976-05-24 | 1981-09-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide |
US4639273A (en) | 1983-05-06 | 1987-01-27 | Morton Thiokol, Inc. | Asphalt-adhesion improving additives prepared by formaldehyde condensation with polyamines |
JPS63182182A (ja) | 1987-01-23 | 1988-07-27 | Fuji Photo Film Co Ltd | 感熱記録材料 |
FR2628864B1 (fr) | 1988-03-21 | 1990-06-15 | France Etat | Procede de segmentation d'un champ de vecteurs vitesse, notamment de vitesses de deplacement de points d'une image dans une sequence d'images |
AU6062590A (en) | 1989-07-07 | 1991-02-06 | Schering Corporation | Pharmaceutically active compounds |
JP2766323B2 (ja) | 1989-07-19 | 1998-06-18 | 株式会社東芝 | 表示調整装置 |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
DE4019307A1 (de) | 1990-06-16 | 1991-12-19 | Bayer Ag | 2-methoximinocarbonsaeureester |
US5258407A (en) | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5449691A (en) | 1991-12-31 | 1995-09-12 | Sterling Winthrop Inc. | 3,4-disubstituted anilines-immunomodulating agents |
FR2687932A1 (fr) | 1992-02-27 | 1993-09-03 | Oreal | Dispersion huile-dans-l'eau susceptible de former des films composites. |
JPH05313169A (ja) | 1992-05-08 | 1993-11-26 | Fuji Photo Film Co Ltd | 液晶配向膜 |
HUT63941A (en) | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
GB9408185D0 (en) * | 1994-04-25 | 1994-06-15 | Fujisawa Pharmaceutical Co | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
DE69512777T2 (de) | 1994-05-31 | 2000-04-27 | Teijin Ltd., Osaka | Naphthalinderivate |
US5532235A (en) | 1995-01-17 | 1996-07-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5536718A (en) | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
DE19523640A1 (de) | 1995-06-29 | 1997-01-02 | Bayer Ag | Substituierte Carbonylaminophenyluracile |
DE19621522A1 (de) | 1996-05-29 | 1997-12-04 | Hoechst Schering Agrevo Gmbh | Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung |
JP3731963B2 (ja) | 1997-01-14 | 2006-01-05 | 株式会社シマノ | 釣り竿用口栓 |
JPH10213820A (ja) | 1997-01-31 | 1998-08-11 | Canon Inc | 液晶素子及び液晶装置 |
TR199902593T2 (xx) | 1997-04-22 | 2000-03-21 | Neurosearch A/S | �kame edilmi� fenil t�revleri, bunlar�n haz�rlanmas� ve kullan�m�. |
CA2319493A1 (en) | 1998-03-18 | 1999-09-23 | Regine Bohacek | Heterocyclic signal transduction inhibitors, compositions containing them |
EP1076641A1 (en) | 1998-04-29 | 2001-02-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
JP2002179651A (ja) | 1998-06-19 | 2002-06-26 | Wakamoto Pharmaceut Co Ltd | ベンズアニリド誘導体及び医薬組成物 |
BR9914638A (pt) | 1998-10-22 | 2001-07-03 | Neurosearch As | Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo |
SK15522001A3 (sk) | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
AU6228000A (en) | 1999-07-23 | 2001-02-13 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
MX226123B (es) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | Benzamidas e inhibidores del factor xa relacionadas. |
US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
AU2001234689A1 (en) | 2000-02-01 | 2001-08-14 | Cor Therapeutics, Inc. | Bivalent phenylene inhibitors of factor xa |
WO2001064643A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
EP1267874A2 (en) | 2000-03-09 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Therapeutic uses of ppar mediators |
MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
DE10033337A1 (de) * | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
MXPA03003002A (es) | 2000-10-05 | 2004-12-06 | Fujisawa Pharmaceutical Co | Compuestos de benzamina como inhibidores de la secrecion de la apo b. |
NZ526003A (en) | 2000-10-20 | 2005-09-30 | Biocryst Pharm Inc | Biaryl compounds as serine protease inhibitors |
HUP0400651A2 (hu) | 2000-11-07 | 2004-06-28 | Bristol-Myers Squibb Company | Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények |
US7056910B2 (en) | 2000-11-28 | 2006-06-06 | Astellas Pharma Inc. | 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof |
DE60126143T2 (de) | 2000-12-06 | 2007-11-15 | Sanofi-Aventis Deutschland Gmbh | Guanidin- und amidin-verbindungen, und ihre verwendung als faktor xa-inhibitoren |
WO2002051397A1 (fr) | 2000-12-22 | 2002-07-04 | Ishihara Sangyo Kaisha, Ltd. | Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
WO2002054077A2 (en) | 2000-12-29 | 2002-07-11 | 7Tm Pharma A/S | Validating biological molecules as drug targets by metal-ion chelates in animal test models |
BR0207996A (pt) | 2001-03-05 | 2004-03-02 | Du Pont | Composto, método de controle de pragas invertebradas e composição para controle das mesmas |
RU2003132706A (ru) | 2001-04-06 | 2005-04-20 | Байокрист Фармасьютикалз, Инк. (Us) | Диариловые соединения в качестве ингибиторов сериновых протеаз |
EP1383760A1 (en) | 2001-04-30 | 2004-01-28 | Fujisawa Pharmaceutical Co., Ltd. | Biarylcarboxamide compounds as apolipoprotein b inhibitors |
WO2002098839A1 (fr) | 2001-06-01 | 2002-12-12 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamides et procede de preparation de ceux-ci |
WO2002101007A2 (en) | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc | Antipathogenic benzamide compounds |
WO2003003008A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Chemical libraries useful for drug discovery processes |
WO2003003009A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
DE10132686A1 (de) | 2001-07-05 | 2003-01-16 | Boehringer Ingelheim Pharma | Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
US20030130343A1 (en) | 2001-08-10 | 2003-07-10 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
JP2005510564A (ja) | 2001-11-28 | 2005-04-21 | 藤沢薬品工業株式会社 | アポリポタンパク質b阻害剤としての複素環式アミド化合物 |
WO2003055477A1 (en) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
WO2003057205A2 (de) | 2002-01-10 | 2003-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL |
WO2003062221A1 (en) | 2002-01-22 | 2003-07-31 | E.I. Du Pont De Nemours And Company | Diamide invertebrate pest control agents |
RU2293721C2 (ru) | 2002-02-28 | 2007-02-20 | Джапан Тобакко Инк. | Сложноэфирные соединения и их применение в медицине |
CN1652759A (zh) | 2002-03-11 | 2005-08-10 | 泰博特克药品有限公司 | 小分子进入抑制剂 |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
JP2003342175A (ja) | 2002-05-24 | 2003-12-03 | Yamanouchi Pharmaceut Co Ltd | 新規なベンゾアゼピン誘導体又はその塩を有効成分とするメニエール病治療剤 |
JP2004043456A (ja) | 2002-05-24 | 2004-02-12 | Yamanouchi Pharmaceut Co Ltd | ベンゾアゼピン誘導体又はその塩を有効成分とする医薬 |
US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
CN1703395A (zh) | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物以及调节凝血的方法 |
US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
JP2004175739A (ja) | 2002-11-28 | 2004-06-24 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US7374749B2 (en) | 2002-12-12 | 2008-05-20 | Ciba Specialty Chemicals Corp. | Amino substituted hydroxyphenyl benzophenone derivatives |
MXPA05006744A (es) | 2002-12-20 | 2005-09-08 | Pfizer Prod Inc | Inhibidores de la proteina microsomal de transferencia de trigliceridos. |
CA2512582C (en) | 2003-01-08 | 2014-07-08 | University Of Washington | Antibacterial agents |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
JP2004315395A (ja) | 2003-04-14 | 2004-11-11 | Yamanouchi Pharmaceut Co Ltd | 新規な安息香酸誘導体又はその塩 |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
US7932272B2 (en) | 2003-09-30 | 2011-04-26 | Eisai R&D Management Co., Ltd. | Antifungal agent containing heterocyclic compound |
JPWO2005040135A1 (ja) | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
DK1714958T3 (en) | 2004-01-28 | 2017-03-20 | Mitsui Chemicals Agro Inc | Amide derivatives, process for their preparation and process for their use as insecticide |
DE102004009238A1 (de) | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
US7427390B2 (en) | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
WO2006007864A1 (en) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
CA2574600C (en) | 2004-07-23 | 2010-08-31 | Pfizer Inc. | Pyridine derivatives |
DE102004050196A1 (de) | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
US20080125432A1 (en) | 2004-12-01 | 2008-05-29 | Devgen Nv | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family |
WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
WO2006068199A1 (ja) | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | 代謝的に安定な3-オキシ-1,2,4-トリアゾール誘導体 |
CN101203484B (zh) | 2005-06-21 | 2012-09-05 | 三井化学株式会社 | 酰胺衍生物及含有该化合物的杀虫剂 |
JP5193861B2 (ja) | 2005-07-07 | 2013-05-08 | アボット・ラボラトリーズ | アポトーシス促進剤 |
JP4580836B2 (ja) | 2005-07-25 | 2010-11-17 | 三井化学アグロ株式会社 | 殺虫殺菌組成物 |
TW200800872A (en) | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
JP2009514875A (ja) | 2005-11-02 | 2009-04-09 | サイトキネティクス・インコーポレーテッド | 化学物質、組成物、および方法 |
WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
JP2009519995A (ja) | 2005-12-20 | 2009-05-21 | ノイロサーチ アクティーゼルスカブ | 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての2−ピリジン−2−イル−キナゾリン誘導体 |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
US7351434B2 (en) | 2006-04-07 | 2008-04-01 | Academia Sinica | Therapeutic Gastrodia extracts |
KR20080109918A (ko) | 2006-04-11 | 2008-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물 |
JP5460324B2 (ja) | 2006-10-12 | 2014-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 治療剤としてのスピロ−オキシインドール化合物の使用 |
US20090325956A1 (en) | 2006-10-13 | 2009-12-31 | Takahiko Taniguchi | Aromatic amine derivative and use thereof |
JP2008106017A (ja) | 2006-10-27 | 2008-05-08 | Tokyo Univ Of Science | Oatp選択的阻害性を有する化合物、及び該化合物を含むoatpの選択的阻害剤 |
AU2007333377B2 (en) | 2006-12-08 | 2014-01-16 | Millennium Pharmaceuticals, Inc. | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
JP4325681B2 (ja) | 2007-02-13 | 2009-09-02 | ソニー株式会社 | 固体撮像装置、撮像装置 |
WO2008104994A2 (en) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
CA2684105C (en) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
WO2008140810A1 (en) | 2007-05-11 | 2008-11-20 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
WO2008156783A2 (en) | 2007-06-18 | 2008-12-24 | University Of Louisville Research Foundation, Inc. | Family of pfkfb3 inhibitors with anti-neoplastic activities |
CN101687815A (zh) | 2007-06-26 | 2010-03-31 | 塞诺菲-安万特股份有限公司 | 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成 |
US20090012091A1 (en) | 2007-07-02 | 2009-01-08 | Kinagen, Inc. | Oximide derivatives and their therapeutical application |
CN101952269B (zh) | 2007-10-10 | 2014-06-25 | 巴斯夫欧洲公司 | 锍盐引发剂 |
JP5473921B2 (ja) | 2007-10-10 | 2014-04-16 | ビーエーエスエフ ソシエタス・ヨーロピア | スルホニウム塩開始剤 |
US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
US8389734B2 (en) * | 2007-10-11 | 2013-03-05 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
MX2010003865A (es) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
WO2009070533A1 (en) | 2007-11-29 | 2009-06-04 | Complegen, Inc. | Methods of inhibiting steroyl coa desaturase |
JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
JP2009209090A (ja) | 2008-03-04 | 2009-09-17 | Mitsui Chemicals Inc | 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法 |
US20100009970A1 (en) | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
JP2010001284A (ja) | 2008-05-20 | 2010-01-07 | Sumitomo Chemical Co Ltd | 化合物及び光学フィルム |
EP3289876B1 (en) | 2008-06-16 | 2022-07-20 | University of Tennessee Research Foundation | Compounds for treatment of cancer |
JP5555236B2 (ja) | 2008-08-25 | 2014-07-23 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ヘッジホッグ経路モジュレーター |
JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
PL2340021T3 (pl) | 2008-09-18 | 2013-04-30 | Hoffmann La Roche | Podstawione pirolidyno-2-karboksyamidy |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
JP5649779B2 (ja) | 2008-11-28 | 2015-01-07 | 住友化学株式会社 | 液晶性組成物及び光学フィルム |
LT2380881T (lt) | 2008-12-26 | 2017-04-10 | Sumitomo Dainippon Pharma Co., Ltd. | Naujas biciklinis heterociklinis junginys |
JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
CN101838264B (zh) | 2009-03-16 | 2014-12-03 | 住友化学株式会社 | 化合物、光学膜和光学膜的制造方法 |
AU2010251050A1 (en) | 2009-05-18 | 2011-11-03 | Orion Corporation | Protease inhibitors |
EP2253617A1 (de) | 2009-05-20 | 2010-11-24 | Bayer CropScience AG | Halogen-substituierte Verbindungen als Pestizide |
WO2010138901A1 (en) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
US8629149B2 (en) | 2009-09-04 | 2014-01-14 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
EP2477625A4 (en) | 2009-09-14 | 2012-10-24 | Phusis Therapeutics Inc | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING PLECKSTRINE HOMOLOGY DOMAIN INHIBITORS AND METHODS OF USE |
US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
JP5375644B2 (ja) | 2010-02-10 | 2013-12-25 | 住友化学株式会社 | 組成物及び光学フィルム |
RU2581367C2 (ru) | 2010-03-01 | 2016-04-20 | Джи Ти Икс, ИНК. | Соединения для лечения рака |
JP2013525368A (ja) | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
US20130158035A1 (en) | 2010-08-24 | 2013-06-20 | Brigham Young University | Antimetastatic compounds |
WO2012026931A1 (en) | 2010-08-25 | 2012-03-01 | Synta Pharmaceuticals Corp. | Method of synthesizing substituted 2-alkyl phenols |
ES2650744T3 (es) | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Inhibidores de la caseína quinasa 1 delta (CK1delta) |
AR085893A1 (es) | 2011-02-02 | 2013-11-06 | Vertex Pharma | Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos |
CA2827311A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
WO2012116440A1 (en) | 2011-03-03 | 2012-09-07 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
EP2686325B1 (en) | 2011-03-14 | 2016-12-14 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
MX2013014326A (es) | 2011-06-20 | 2014-01-23 | Du Pont | Compuestos heterociclicos para tratar infecciones por helmintos. |
CN103765212A (zh) | 2011-06-27 | 2014-04-30 | 杰克逊实验室 | 治疗癌症和自体免疫性疾病的方法和组合物 |
SI2573073T1 (sl) | 2011-09-26 | 2015-02-27 | Sanofi | Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba |
CN103012397B (zh) | 2011-09-26 | 2017-03-01 | 赛诺菲 | 吡唑并喹啉酮衍生物、其制备方法及其治疗用途 |
US9169246B2 (en) | 2011-09-26 | 2015-10-27 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
PE20141682A1 (es) | 2011-10-26 | 2014-11-14 | Pfizer Ltd | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio |
GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
EP2606726A1 (de) | 2011-12-21 | 2013-06-26 | Bayer CropScience AG | N-Arylamidine-substituierte trifluoroethylsulfid-Derivate als Akarizide und Insektizide |
US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
US9403839B2 (en) | 2012-01-16 | 2016-08-02 | Vertex Pharmaceuticals Incorporated | Pyran-spirocyclic piperidine amides as modulators of ion channels |
WO2013114250A1 (en) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
US8481479B1 (en) | 2012-03-07 | 2013-07-09 | Shaker A. Mousa | Formulations of factor VIIa inhibitors and utility |
US8980823B2 (en) | 2012-03-07 | 2015-03-17 | Shaker A. Mousa | Formulations of Factor VIIa inhibitors and utility |
US20150210717A1 (en) | 2012-09-13 | 2015-07-30 | Baden-Württemberg Stiftung Gmbh | Specific inhibitors of protein p21 as therapeutic agents |
WO2014055644A2 (en) | 2012-10-02 | 2014-04-10 | New York University | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay |
US20150272939A1 (en) | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
US20140200215A1 (en) | 2013-01-15 | 2014-07-17 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
SG11201505952WA (en) | 2013-01-31 | 2015-08-28 | Vertex Pharma | Quinoline and quinazoline amides as modulators of sodium channels |
KR102226588B1 (ko) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 아미드 |
PE20151781A1 (es) | 2013-01-31 | 2015-12-02 | Vertex Pharma | Piridonamidas como moduladores de canales de sodio |
CN103961348B (zh) | 2013-02-05 | 2016-08-17 | 上海交通大学医学院 | Senp1小分子抑制剂及其应用 |
US9580400B2 (en) | 2013-02-26 | 2017-02-28 | Northeastern University | Cannabinergic nitrate esters and related analogs |
WO2014149207A2 (en) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Benzimidazole-based insecticidal compositions and related methods |
JP5902641B2 (ja) | 2013-03-27 | 2016-04-13 | 富士フイルム株式会社 | 光干渉顔料およびその製造方法 |
JP2014232188A (ja) | 2013-05-29 | 2014-12-11 | コニカミノルタ株式会社 | セルロースアシレートフィルム、円偏光板及び画像表示装置 |
WO2014192681A1 (ja) | 2013-05-31 | 2014-12-04 | コニカミノルタ株式会社 | 樹脂組成物、光学部材、光学フィルム、偏光板、円偏光板及び画像表示装置 |
WO2015030898A2 (en) | 2013-06-07 | 2015-03-05 | The Regents Of The University Of California | Micromechanical resonant switches and charge pumps |
EP3010512B1 (en) | 2013-06-18 | 2017-12-27 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
AU2014289663B2 (en) | 2013-07-12 | 2019-03-07 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Cystobactamides |
CA2918365C (en) | 2013-07-19 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
AU2014295000A1 (en) | 2013-07-25 | 2016-02-18 | Fondazione Telethon | Inhibitors of FAPP2 and uses thereof |
WO2015014900A1 (en) | 2013-07-31 | 2015-02-05 | Minoryx Therapeutics S.L. | Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof |
KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
KR102435145B1 (ko) | 2013-12-13 | 2022-08-24 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드의 프로드럭 |
US9204150B2 (en) | 2014-02-26 | 2015-12-01 | Intel Corporation | Techniques for evaluating compressed motion video quality |
US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
WO2016022626A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
WO2016040449A1 (en) | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
EP2997966A1 (en) | 2014-09-16 | 2016-03-23 | Sanofi | Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders |
CN106317027A (zh) | 2015-06-15 | 2017-01-11 | 山东轩竹医药科技有限公司 | 杂芳基酰胺类衍生物及其作为tgr5激动剂的应用 |
EP3350181B1 (en) | 2015-09-02 | 2023-11-01 | The Regents of The University of California | Her3 ligands and uses thereof |
WO2017062751A1 (en) | 2015-10-08 | 2017-04-13 | The Regents Of The University Of California | Compounds and methods for promoting stress resistance |
US20180305334A1 (en) | 2015-10-14 | 2018-10-25 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
CN114539284A (zh) | 2016-03-16 | 2022-05-27 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
PE20191153A1 (es) | 2016-09-28 | 2019-09-05 | Blade Therapeutics Inc | Moduladores de calpainas y usos terapeuticos de los mismos |
EP3519533B1 (en) | 2016-09-28 | 2020-12-16 | Merck Patent GmbH | Polymerisable liquid crystal material and polymerised liquid crystal film |
WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
TW201900638A (zh) | 2017-04-20 | 2019-01-01 | 加州大學董事會 | K-ras調節劑 |
WO2018202681A1 (en) | 2017-05-04 | 2018-11-08 | Bayer Cropscience Aktiengesellschaft | Use of disubstituted benzenes to control insecticide-resistant pests |
JP2019015998A (ja) | 2017-07-03 | 2019-01-31 | 東芝テック株式会社 | 情報処理装置およびプログラム |
BR112020000553A2 (pt) | 2017-07-11 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | carboxamidas como moduladores de canal de sódio |
WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
AU2018319016B2 (en) | 2017-08-17 | 2023-08-31 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
US20210363134A1 (en) | 2018-01-30 | 2021-11-25 | Pi Industries Ltd. | Novel anthranilamides, their use as insecticide and processes for preparing the same |
US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
WO2019207081A1 (en) | 2018-04-27 | 2019-10-31 | Merck Patent Gmbh | Polymerisable liquid crystal material and polymerised liquid crystal film |
KR20210005160A (ko) | 2018-04-27 | 2021-01-13 | 메르크 파텐트 게엠베하 | 중합성 액정 물질 및 중합된 액정 필름 |
WO2019241787A1 (en) | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use |
WO2020051207A2 (en) | 2018-09-04 | 2020-03-12 | Magenta Therapeutics Inc. | Aryl hydrocarbon receptor antagonists and methods of use |
EP3866798A4 (en) | 2018-10-15 | 2022-07-13 | Dana-Farber Cancer Institute, Inc. | ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES |
EP3894392A4 (en) | 2018-12-11 | 2022-08-24 | Duke University | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
WO2020139748A1 (en) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
CN113302262A (zh) | 2019-01-22 | 2021-08-24 | 默克专利股份有限公司 | 液晶聚合物膜的制备方法 |
AU2019427489A1 (en) | 2019-01-28 | 2021-07-22 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
CA3133753A1 (en) | 2019-03-15 | 2020-09-24 | The General Hospital Corporation | Novel small molecule inhibitors of tead transcription factors |
WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
CN113785032A (zh) | 2019-04-30 | 2021-12-10 | 默克专利股份有限公司 | 反应性介晶 |
US20220324880A1 (en) | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
-
2018
- 2018-07-11 BR BR112020000553-3A patent/BR112020000553A2/pt not_active Application Discontinuation
- 2018-07-11 CN CN201880058540.1A patent/CN111065383A/zh active Pending
- 2018-07-11 MA MA049566A patent/MA49566A/fr unknown
- 2018-07-11 JP JP2020501369A patent/JP7277431B2/ja active Active
- 2018-07-11 WO PCT/US2018/041649 patent/WO2019014352A1/en unknown
- 2018-07-11 EP EP18746526.5A patent/EP3651752A1/en active Pending
- 2018-07-11 TN TNP/2020/000001A patent/TN2020000001A1/en unknown
- 2018-07-11 UY UY0001037806A patent/UY37806A/es not_active Application Discontinuation
- 2018-07-11 TW TW107123989A patent/TW201920081A/zh unknown
- 2018-07-11 SG SG11202000230VA patent/SG11202000230VA/en unknown
- 2018-07-11 CA CA3069720A patent/CA3069720A1/en not_active Abandoned
- 2018-07-11 US US16/032,799 patent/US10647661B2/en active Active
- 2018-07-11 KR KR1020207003933A patent/KR20200026987A/ko unknown
- 2018-07-11 PE PE2020000022A patent/PE20201164A1/es unknown
- 2018-07-11 JO JOP/2020/0001A patent/JOP20200001A1/ar unknown
- 2018-07-11 AU AU2018300150A patent/AU2018300150A1/en not_active Abandoned
- 2018-07-11 CR CR20200064A patent/CR20200064A/es unknown
-
2020
- 2020-01-08 PH PH12020500066A patent/PH12020500066A1/en unknown
- 2020-01-08 DO DO2020000004A patent/DOP2020000004A/es unknown
- 2020-01-08 CO CONC2020/0000145A patent/CO2020000145A2/es unknown
- 2020-01-09 IL IL271948A patent/IL271948A/en unknown
- 2020-01-10 CL CL2020000075A patent/CL2020000075A1/es unknown
- 2020-01-15 EC ECSENADI20203147A patent/ECSP20003147A/es unknown
- 2020-03-19 US US16/824,255 patent/US11603351B2/en active Active
-
2022
- 2022-12-13 US US18/065,208 patent/US20230286907A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TN2020000001A1 (en) | 2021-10-04 |
US20210094906A1 (en) | 2021-04-01 |
IL271948A (en) | 2020-02-27 |
US20190016671A1 (en) | 2019-01-17 |
US11603351B2 (en) | 2023-03-14 |
EP3651752A1 (en) | 2020-05-20 |
US10647661B2 (en) | 2020-05-12 |
WO2019014352A1 (en) | 2019-01-17 |
CR20200064A (es) | 2020-08-03 |
CA3069720A1 (en) | 2019-01-17 |
PE20201164A1 (es) | 2020-10-28 |
TW201920081A (zh) | 2019-06-01 |
CN111065383A (zh) | 2020-04-24 |
MA49566A (fr) | 2020-05-20 |
JOP20200001A1 (ar) | 2022-10-30 |
CL2020000075A1 (es) | 2020-07-31 |
JP2020526561A (ja) | 2020-08-31 |
AU2018300150A1 (en) | 2020-01-30 |
CO2020000145A2 (es) | 2020-01-17 |
UY37806A (es) | 2020-01-31 |
KR20200026987A (ko) | 2020-03-11 |
US20230286907A1 (en) | 2023-09-14 |
JP7277431B2 (ja) | 2023-05-19 |
SG11202000230VA (en) | 2020-02-27 |
PH12020500066A1 (en) | 2020-09-28 |
ECSP20003147A (es) | 2020-02-28 |
BR112020000553A2 (pt) | 2020-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20003147A (es) | Carboxamidas como moduladores de los canales de sodio | |
UY38979A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
CO2019013021A2 (es) | Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio | |
ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
UY35288A (es) | Piridonamidas como moduladores de canales de sodio | |
CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
PE20151427A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
DOP2019000184A (es) | Inhibidores selectivos de jak1 | |
UY39800A (es) | N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio | |
CO2017011017A2 (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
CR20160047A (es) | Inhibidores de rorc2 y sus métodos de uso | |
UY36322A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CO2019004143A2 (es) | Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa | |
CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino | |
EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 | |
EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
EA202090268A1 (ru) | Карбоксамиды в качестве модуляторов натриевых каналов | |
ECSP17025904A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos |